Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 19INDUSTRY 15NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1

Interventions

Cytarabine 61Daunorubicin 28Specimen Handling 24Etoposide 24Azacitidine 22Decitabine 19Cyclophosphamide 19fludarabine phosphate 18Filgrastim 18Biopsy 18Busulfan 17Idarubicin 16venetoclax 15Peripheral Blood Stem Cell Transplantation 15Mitoxantrone 15Injections 14Vorinostat 12tipifarnib 11Bortezomib 10decitabine and cedazuridine drug combination 9Radiotherapy 9Methotrexate 9alvocidib 8Cyclosporine 8sargramostim 7Melphalan 7Antilymphocyte Serum 7laromustine 6fludarabine 6aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Acute × midostaurin × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡